Welcome to our dedicated page for BIOCRYST PHARMACEUTICALS SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) director Jon P. Stonehouse received a grant of 644 shares of Common Stock on August 31, 2026, at a value of $9.70 per share. The shares were issued in lieu of 50% of a quarterly cash Board Member retainer of $12,500. Following this award, he holds 1,340,419 shares directly, plus 40,000 shares held indirectly in each of two irrevocable trusts for Caroline and Samuel Stonehouse. No Rule 10b5‑1 trading plan is reported.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Milne Jill C. reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Jill C. Milne received a grant of 1,288 shares of Common Stock on August 31, 2026, as a board compensation award. The shares were issued in lieu of a $12,500 quarterly cash Board Member retainer, bringing her directly held stake to 33,226 shares. No Rule 10b5-1 trading plan is reported for this transaction.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Vincent Milano received an award of 1,159 shares of Common Stock on August 31, 2026. These shares were issued in lieu of 50% of his quarterly Board Chair cash retainer of $22,500, equating to a value of $9.70 per share. Following this grant, Milano directly holds 109,642 shares of Biocryst common stock. No transactions were reported under a Rule 10b5-1 trading plan.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) director Amy E. McKee received a grant of 644 shares of Common Stock on August 31, 2026, valued at $9.70 per share. The shares were issued in lieu of 50% of her $12,500 quarterly Board member cash retainer, bringing her direct holdings to 47,821 shares. No Rule 10b5-1 trading plan is reported.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Steven Frank received a grant of 1,288 shares of Common Stock on August 31, 2026 as a grant/award acquisition. The shares were issued at $9.70 per share in lieu of a $12,500 quarterly cash Board Member retainer, bringing his directly held stake to 36,747 shares. No Rule 10b5-1 trading plan is reported for this transaction.
RA Capital Management, L.P. and affiliated entities reported a passive ownership position in BioCryst Pharmaceuticals, Inc. as of June 30, 2026. RA Capital Healthcare Fund, L.P. directly holds 15,827,186 shares of BioCryst common stock, representing 6.2% of the outstanding shares based on 255,265,000 shares outstanding.
The Fund has delegated to RA Capital the sole power to vote and dispose of these shares, resulting in shared voting and dispositive power over 15,827,186 shares and no sole power. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners for Section 13(d) purposes but each disclaims beneficial ownership except for determining reporting obligations.
State Street Corporation reports beneficial ownership of common stock of BioCryst Pharmaceuticals, Inc. as an institutional holder. State Street reports beneficial ownership of 15,191,098 shares of BioCryst common stock, representing 6% of the class.
State Street has no sole voting or dispositive power over these shares. It reports shared voting power over 14,586,276 shares and shared dispositive power over 15,191,098 shares, primarily through its investment management subsidiaries such as SSGA Funds Management, Inc. and various State Street Global Advisors entities.
BioCryst Pharmaceuticals reported Q2 2026 revenues of $218,250 thousand, up from $163,353 thousand a year earlier, driven by ORLADEYO and higher license and other revenues. Q2 net income was $78,395 thousand, or $0.30 per diluted share, and income from operations was $98,465 thousand.
For the first six months of 2026, revenues were $374,663 thousand, but a $697,761 thousand acquired in‑process R&D expense related to the Astria Therapeutics acquisition led to a net loss of $643,417 thousand, or $2.59 per share. Total consideration for Astria was $874,313 thousand, mostly allocated to the navenibart IPR&D asset and funded in part by a $400,000 thousand term loan under a Blackstone credit agreement. At June 30, 2026, cash and cash equivalents were $154,972 thousand and short‑term investments were $197,601 thousand, while royalty financing obligations totaled $426,789 thousand and the secured term loan balance was $395,400 thousand, contributing to stockholders’ deficit of $454,289 thousand. Management states existing financial resources are expected to fund operations for at least 12 months.
BioCryst Pharmaceuticals reported strong second-quarter 2026 results, with total revenue of $218.3 million, up 34% year over year, and ORLADEYO revenue of $158.2 million. The company generated a GAAP operating profit of $98.5 million and a non-GAAP operating profit of $113.2 million, alongside positive free cash flow even excluding a licensing upfront payment.
BioCryst entered a European licensing agreement for navenibart, receiving $70.0 million upfront, with up to $275.0 million in potential milestones and tiered royalties of 18%–30%; $55.7 million of related revenue was recognized in the quarter. Full-year 2026 guidance now targets ORLADEYO revenue of $625–$645 million, total revenue of $690–$715 million, and improved non-GAAP operating expenses of $420–$440 million.
Operationally, BioCryst began shipping ORLADEYO oral pellets to pediatric hereditary angioedema patients, completed enrollment in the pivotal ALPHA-ORBIT navenibart trial, and advanced BCX17725 toward data by year-end 2026. The company is discontinuing internal discovery programs and closing its Birmingham facility by the end of 2026 to prioritize external innovation, while appointing a new Chief Scientific Officer to lead this strategy.
BioCryst Pharmaceuticals plans to discontinue its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama as part of a strategic effort to strengthen its rare disease pipeline.
The company now expects to incur $6.2–$7.5 million in one-time employee termination and severance expenses related to this plan, of which approximately $5.3–$6.6 million are expected to be cash outflows. Additional costs tied to closing the Birmingham facility, including potential contract and lease termination and asset impairment charges, are still being analyzed, and management states it cannot yet estimate these amounts in good faith. The company indicates it will provide updated cost estimates in a future report and highlights that these expectations involve forward-looking statements subject to risks and uncertainties.